Zie ook in gerelateerde artikelen 

22 oktober 2023: Bron: artsencollectief en New Microbes and New Infections Volume 55, October 2023, 101172

Uit een Belgische retrospectieve studie met 3885 deelnemers waarvan 352 patiënten die waren opgenomen in het ziekenhuis wegens een Covid-19 - coronavirus besmetting een behandeling kregen met hydroxychloroquine plus azithromycine en een controlegroep van 3533 patiënten die standaard beste zorg kregen blijkt de combinatiebehandeling van hydroxychloroquine plus azithromycine 57 procent minder kans op overlijden te hebben gegeven. En de resultaten golden voor alle leeftijdsgroepen.

De uitkomst van het onderzoek was, dat de met hydroxychloroquine met of zonder azithromycine behandelde patiënten na 28 dagen een 57% lagere sterftekans hadden dan de controlepatiënten in een analyse die ook rekening hield met ernst van de ziekte en onderliggende aandoeningen. Het verschil in overleving was zichtbaar in alle leeftijdscategorieën. Zie onderstaande grafiek

Fig. 2. Association between group (HCQ vs no-HCQ) and mortality (status at 28 days), controlling for age. Treatment with hydroxychloroquine (HCQ) plus azithromycin was associated with a reduction in mortality in all age groups. The adjusted common relative risk for mortality after controlling for age was 0.7597 (95% CI 0.6053–0.9534. p ​= ​0.0097).


En dan te bedenken dat deze combinatiebehandeling eerder door een vervalste publicatie in The Lancet, zie deze PDF, in bijna alle landen is stopgezet. Een van de weinige studies en onderzoekers die ermee zijn  doorgegaan zijn deze Belgische onderzoekers.

En Nederlandse artsen, bv  die deze behandelingen zouden geven zouden vervolgd worden voor meewerken aan kwakzalverij. En Minister Kuipers handhaaft die straf nog steeds.  

Het artsencollectief schrijft over deze studie een kort artikel: 

‘Kwakzalverij’ blijkt toch te werken


Het volledige Belgische studieverslag is gratis in te zien of te downloaden: 

Efficacy and safety of in-hospital treatment of Covid-19 infection with low-dose hydroxychloroquine and azithromycin in hospitalized patients: A retrospective controlled cohort study

https://doi.org/10.1016/j.nmni.2023.101172Get rights and content
Under a Creative Commons license
open access

Highlights

  • •

    Retrospective study of 3885 patients (352 treatment, 3533 control).

  • •

    Hydroxychloroquine and azithromycin versus standard of care.

  • •

    OR for mortality in the treatment group was 0.635 vs controls. This survival benefit was consistent in all age groups.

  • •

    No torsade de pointes or malignant ventricular arrhythmias observed during treatment.

Abstract

Objectives

In this study we evaluate the efficacy and safety of a treatment protocol with standard dose of hydroxychloroquine plus azithromycin in patients hospitalized with COVID-19 infection.

Methods

We conducted a retrospective analysis to compare the 28-day mortality rate in 352 patients treated with hydroxychloroquine with or without azithromycin (HCQ-group) in our hospital with a contemporary control group of 3533 patients receiving standard of care from the Belgian Collaborative Group on COVID-19 Hospital Surveillance.

Results

All patients who received at least one dose of treatment were included in the analysis. A statistically significant reduction in crude mortality rate at 28 days was observed in the HCQ-group compared to standard of care (16.8% vs 25.9%,p ​= ​0.001).

Patients in the treatment group were on average younger (69,7 vs73,1 years, p ​= ​0,0002), were less likely to smoke or to have malignancy and more likely to be male. Patients in the treatment group were more likely to be obese, immunocompromised or to have arterial hypertension, liver disease and lung disease.

After adjustment for these variables the OR for mortality was 0.635 (95%CI 0.464–0.875). Patients who did not receive HCQ had a 57% higher risk of mortality. A survival benefit in the treatment group was consistent across all age groups. 13 patients discontinued treatment due to side effects (4 with QTc-prolongation>60msec (1.1%) and 9 because of gastro-intestinal symptoms (2.55%)). No episodes of ventricular arrhythmia or torsade de pointes were recorded during treatment.

Conclusion

Treatment of COVID-19 using a combination of hydroxychloroquine plus azithromycin was safe and was associated with a statistically significant mortality benefit in the treatment of COVID-19 infection in hospitalized patients. Our findings do not support the current negative recommendations regarding this treatment.

Referentie

  1. Gert Meeus, Frauke Van Coile, Hans Pottel, Ann-Sophie Michel, Ortwin Vergauwen, Katy Verhelle, Stoffel Lamote, Mathias Leys, Michaël Boudewijns, Pieter Samaey (2023).
    Efficacy and safety of in-hospital treatment of Covid-19 infection with low-dose hydroxychloroquine and azithromycin in hospitalized patients: A retrospective controlled cohort study. New Microbes and New Infections 55: 101172. https://doi.org/10.1016/j.nmni.2023.101172.

Declaration of competing interest

The authors declare they have no conflicting interest to declare.

Acknowledgements

The authors would like to thank Dominique van Beckhoven and Sciensano for their generous cooperation and kind permission to use the Database from the Belgian Collaborative Group on COVID-19 Hospital Surveillance. The use of this dataset made an enormous contribution to the strength of our findings. We also wish to thank all the medical staff, pharmacists, nurses and coworkers of the AZ Groeninge hospital for their hard work and unyielding commitment to our patients in the very difficult conditions that we were confronted with during the first phase of the pandemic. Without their dedication and meticulous work it would have been impossible to perform our data analysis.

References




hydroxychloroquine, azithromycine, covid-19, coronavirus, besmetting, kans op overlijden, Belgische studie


Plaats een reactie ...

Reageer op "Hydroxychloroquine plus azithromycine gaf 57 procent minder kans op overlijden aan coronavirus besmetting bij patienten opgenomen in het ziekenhuis blijkt uit grote Belgische studie"


Gerelateerde artikelen
 

Gerelateerde artikelen

Aan de studie dat hydroxychloroquine >> Hydroxychloroquine vermindert >> Hydroxychloroquine plus azitromycine >> Corona virus: Artikelen over >>